The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. executive Joshua Jergensen, President & COO, reported two open-market sales of 40,000 shares of common stock on August 12, 2026. The transactions, executed under a Rule 10b5-1 trading plan adopted on March 12, 2026, occurred at weighted average prices of $44.5299 and $45.6981 per share, each reflecting multiple trades within disclosed price ranges.
Cohen & Steers and affiliates report their beneficial ownership position in PACS Group, Inc. common stock. They beneficially own 7,396,136 shares, representing 4.67% of the class, which is below the 5% threshold referenced for significant holders.
The group has sole voting power over 6,773,504 shares and sole dispositive power over 7,396,136 shares, with no shared voting or dispositive power. Subsidiaries Cohen & Steers Capital Management, UK, Asia, and Ireland entities hold the securities for the benefit of their respective account holders, who are entitled to dividends and sale proceeds.
PACS Group, Inc. reported strong second quarter 2026 results, with revenue of $1.43 billion, up 9.1% year over year. Net income was $76.3 million, an increase of 49.8%, and diluted EPS was $0.47, up 51.6%. Adjusted EPS was $0.63, up 34.0%, Adjusted EBITDA was $166.8 million, up 24.6%, and Adjusted EBITDAR reached $261.5 million.
Same‑store skilled nursing revenue grew 5.8%, with occupancy rising to 90.6% from 89.1%. Overall occupancy was 90.4% versus an industry average of 79.5%, and skilled mix increased to 30.0%. Cash provided by operating activities was $371.8 million for the first half of 2026, and available liquidity was $756.6 million, including $164.5 million of cash and cash equivalents.
The company is expanding through the previously announced Eduro Healthcare transaction for 34 skilled nursing facilities totaling 3,633 beds, having closed on 20 Texas facilities as of August 1, 2026. PACS raised its 2026 guidance, lifting Adjusted EBITDA to $640–$660 million and revenue to $5.75–$5.85 billion, reflecting contributions from the closed Eduro Texas facilities.
PACS Group, Inc. President & COO Joshua Jergensen reported three open-market sales totaling 40,000 shares of common stock on July 15, 2026. The shares were sold at weighted average prices between $43.74 and $45.78 per share under a Rule 10b5-1 trading plan adopted March 12, 2026. The transactions were reported as sales of stock held in his direct ownership, and he continues to hold PACS Group common stock afterward.
PACS Group, Inc. director and ten percent owner Mark Hancock reported open-market sales of 13,628 shares of common stock on July 14 and 15, 2026. The shares were sold at weighted average prices of $45.0350 and $45.0525 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following these transactions, Hancock directly holds 53,906,884 shares of PACS Group common stock.
Mark Hancock, a shareholder of PACS, has submitted a notice under Rule 144 covering the planned sale of 15,827,237 common shares through Citigroup Global Markets Inc on the NYSE, with an aggregate market value of 150114.93 and an approximate sale date of July 15, 2026.
Hancock acquired 54,626,199 common shares for cash from the issuer at its formation on March 1, 2023. Over the past three months, he has reported multiple block sales of common stock, including 153,254 shares on June 15, 2026 for 5568759.95 and 83,066 shares on June 16, 2026 for 2982385.05.
A Form 144 notice for PACS reports that Mark Hancock plans to sell 10,296 shares of PACS common stock through Citigroup Global Markets Inc. The planned sale has an aggregate market value of $463,680.36, with the shares listed on the NYSE and an approximate sale date of 07/14/2026. The notice also states that there are 15,827,237 shares of this class outstanding.
The common shares being sold were originally acquired on 03/01/2023 as part of the formation of the issuer, for cash. The Form 144 disclosure lists multiple PACS common stock sales by Mark Hancock over the prior three months, including transactions such as 153,254 shares sold on 06/15/2026 and 142,163 shares sold on 07/06/2026 for multi‑million dollar proceeds.
PACS Group, Inc. director and ten-percent owner Mark Hancock reported open-market sales of common stock totaling 25,304 shares on July 8–9, 2026, at weighted average prices of about $45 per share. After these transactions, he directly holds more than 53.9 million shares of PACS Group common stock. The sales were effected pursuant to a Rule 10b5-1 trading plan and were executed in multiple trades within disclosed price ranges.